Bain Capital
Ron Renaud serves as the President and CEO of Kailera Therapeutics and holds a board member position at Cardurion Pharmaceuticals. Renaud is also a Senior Advisor in Life Sciences and a Partner at Bain Capital. Additionally, Renaud chairs Upstream Bio and is a board member of Jnana Therapeutics. Academically, Renaud earned an MBA in Finance from the USC Marshall School of Business, completing studies from 1997 to 1999, and holds a BA in Psychology from Saint Anselm College, which was obtained from 1986 to 1990.
This person is not in the org chart
This person is not in any teams
Bain Capital
62 followers
Bain Capital is one of the world’s leading private, multi-asset investment firms, specializing in private equity, credit, public equity, venture capital and real estate, among other asset classes, across various industries. The firm manages approximately $175 billion in assets. Founded in 1984, Bain Capital’s investment strategy features a consulting-focused approach that prioritizes close relationships with management teams across the globe. Throughout all of its endeavors, Bain Capital retains a steadfast commitment to responsible business practices and premier environmental, social and governance (ESG) standards. The company operates via 24 locations worldwide, employing more than 1,600 team members. The firm has supported a wide range of charity and nonprofit organizations through the Bain Capital Community Partnership. Through the partnership, Bain Capital employees serve on more than 220 nonprofit boards. In addition, Bain Capital Children's Charity (BCCC) provides financial support to philanthropic organizations invested in providing opportunities for the youth. Founded in 1997, BCCC contributes to hundreds of organizations dedicated to education, healthcare, child development, and mentoring.